Ifosfamide

Ifosfamide · IFOSFAMIDE 50 mg/mL · Injection · Intravenous · Hikma Pharmaceuticals USA Inc.

NDC 00143-9530-01 · 1 VIAL in 1 BOX / 60 mL in 1 VIAL · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. It is in shortage right now — FDA lists the reason as “demand increase for the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$107.54

Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 GM

$27.613

HCPCS J9208 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$2,889

34 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA076619
TE code: AP
Approval date: Jun 29, 2011
Patents / exclusivity: None on file

Shortage history

In shortage now — Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)Jun 12, 2026
Demand increase for the drug
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months
In shortage now — Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)Jun 12, 2026
Demand increase for the drug
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ifosfamide (Injection)

Labeler	Strength	First seen	Last seen
Hikma Pharmaceuticals USA Inc.	IFOSFAMIDE 50 mg/mL	Jul 15, 2026	Sep 3, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ifosfamide — NDC 00143-9530-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00143953001.

Free to cite with attribution — see how the data is put together.